TUMOR PROGRESSION AND RECURRENCE PROGRAM Project Summary The major goals of the Tumor Progression and Recurrence (TPR) Program are to understand the molecular mechanisms that promote tumor progression and recurrence and use this knowledge to develop novel strategies to treat cancer, particularly those with high rates of recurrence, relentless progression, or high incidence/high mortality in the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) catchment area. These goals will be achieved by the Program members' research around two central themes: cellular signaling and the tumor microenvironment. The cellular signaling theme reflects a focus on mechanisms that are both important for cancer progression and potential targets for therapeutics. The tumor microenvironment theme focuses on interactions between cancer cells and other cell types within tumors that promote tumor progression and facilitate recurrence. The research of the TPR Program centers particularly on malignant gliomas, including glioblastoma; metastatic breast cancer; and prostate cancer. In all of these, tumor progression and/or recurrence are particularly important. The focus on prostate cancer also reflects its high rates of occurrence in the WFBCCC catchment area, especially among African Americans. The Program has two Specific Aims.
Aim 1 is to determine the signaling pathways and molecular targets in cancer cells and other cell types in the tumor microenvironment that promote tumor progression and recurrence.
Aim 2 is to identify novel therapeutic approaches for difficult-to-treat cancers, based on disrupting signaling between cancer cells and other cells in the tumor microenvironment, and drug delivery targeted to cells in the tumor microenvironment. Examples include targeting interactions of Ephrin ligands and their Eph receptors and delivery of cytotoxic load, development of peptides that target the Mas receptor, and development of oncolytic viruses that target defects in antiviral signaling in cancers. New members recruited into the Program since the last review further strengthen the research portfolio around the two Program themes. The Program has 31 members from 14 different departments or sections, including Biochemistry, Biomedical Engineering, Cancer Biology, Comparative Medicine, Human Genomics, Microbiology and Immunology, Molecular Medicine, Neurosurgery, Pathology, Radiation Oncology, Radiology, Regenerative Medicine, and Surgery. Program members have $4.4M in extramural peer-reviewed funding (excluding $.7M in peer-reviewed training grants), of which 37.2% is from the NCI. Among the members' 247 publications, 23.5% were intra-programmatic, 17.0% were inter-programmatic, and 66.4% were inter-institutional, demonstrating the collaborative spirit and national and international stature of the Program's research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-43
Application #
9422687
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
43
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Chouliaras, Konstantinos; Levine, Edward A; Fino, Nora et al. (2017) Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol 24:890-897
Wang, Lulu; Habib, Amyn A; Mintz, Akiva et al. (2017) Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential. Mol Imaging 16:1536012117708722
Keim-Malpass, Jessica; Mihalko, Shannon L; Russell, Greg et al. (2017) Problems Experienced by Ovarian Cancer Survivors During Treatment. J Obstet Gynecol Neonatal Nurs 46:544-554
Ivey, Jill W; Latouche, Eduardo L; Richards, Megan L et al. (2017) Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J 113:472-480
Rohlfing, Matthew L; Mays, Ashley C; Isom, Scott et al. (2017) Insurance status as a predictor of mortality in patients undergoing head and neck cancer surgery. Laryngoscope 127:2784-2789
Soto-Pantoja, David R; Wilson, Adam S; Clear, Kenysha Yj et al. (2017) Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget 8:80545-80559
Park, Sun H; Eber, Matthew R; Tsuzuki, Shunsuke et al. (2017) Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Sci Rep 7:17428
Andrews, Rachel N; Metheny-Barlow, Linda J; Peiffer, Ann M et al. (2017) Cerebrovascular Remodeling and Neuroinflammation is a Late Effect of Radiation-Induced Brain Injury in Non-Human Primates. Radiat Res 187:599-611
Carpenter, Richard L; Sirkisoon, Sherona; Zhu, Dongqin et al. (2017) Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget 8:73947-73963
Wajih, Nadeem; Basu, Swati; Jailwala, Anuj et al. (2017) Potential therapeutic action of nitrite in sickle cell disease. Redox Biol 12:1026-1039

Showing the most recent 10 out of 481 publications